Increased immune activity in the tumor before treatment is correlated with the efficacy of nab-paclitaxel and pegylated liposomal doxorubicin when combined with anti-PD-1/PD-L1 therapy (Table 1). This evidence concerns the gene CD274 and neoplasm.